StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Free Report) in a research report report published on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.
Bellerophon Therapeutics Stock Down 25.5 %
Shares of BLPH opened at $0.01 on Friday. The stock has a market capitalization of $146,796.00, a P/E ratio of -0.01 and a beta of 0.74. Bellerophon Therapeutics has a twelve month low of $0.01 and a twelve month high of $0.02. The firm has a fifty day simple moving average of $0.03 and a two-hundred day simple moving average of $0.03.
Bellerophon Therapeutics Dividend Announcement
The firm also recently declared a dividend, which was paid on Wednesday, December 18th. Investors of record on Friday, December 20th were issued a dividend of $0.019 per share. The ex-dividend date of this dividend was Thursday, December 19th. This represents a yield of 117.8%.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.
Recommended Stories
- Five stocks we like better than Bellerophon Therapeutics
- How to Start Investing in Real Estate
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- Dividend Capture Strategy: What You Need to Know
- Oilfield Leader SLB: An AI Name You Need to Know
- Insider Trading – What You Need to Know
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
